NeOnc Technologies prices $15M direct offering at $4.20 per share

NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI), a clinical-stage biopharmaceutical company focused on central nervous system cancers, announced the pricing of a $15 million registered direct offering priced at-the-market under Nasdaq rules.

According to the press release, the company entered into securities purchase agreements with new and existing healthcare-focused institutional investors for the purchase and sale of 3,571,430 shares of common stock, or pre-funded warrants in lieu thereof, at a combined purchase price of $4.20 per share.

The offering also includes accompanying warrants to purchase up to 3,571,430 shares of common stock. Each warrant is immediately exercisable at $4.20 per share and will expire five years from the date of issuance. Pre-funded warrants carry an exercise price of $0.0001 per share and expire when exercised in full.

Gross proceeds are estimated at approximately $15 million before placement agent fees and other offering expenses. The offering was expected to close on or about September 10, 2026, subject to customary closing conditions.

Roth Capital Partners and A.G.P./Alliance Global Partners are acting as co-placement agents for the transaction.

The offering is being made pursuant to a shelf registration statement on Form S-3 previously filed with the U.S. Securities and Exchange Commission, which became effective on April 9, 2026.

You May Also Be Interested In

• Axogen prices $208.7M stock offering to fund BioCircuit acquisition
• Arrow Financial to acquire New York insurance agency by end of Q3 2026
• Avalanche Treasury names Virginia Gambale to its board